A Fresh Take on GLP-1 Support
US$ 24.60
glp 1 abuse GLP-1 receptor agonists show promise in treating substance use disorders GLP-1s like Ozempic transformed weight
Description
In recent years, a revolutionary class of medications known as GLP-1 receptor agonists has transformed the landscape of medical weight management
In the PIONEER 6 trial, involving patients with T2D and high CV risk (including established CVD, chronic kidney disease, or age 50 years with risk factors), oral semaglutide demonstrated non-inferiority for MACE (HR 0.79
Weight loss results with Ozempic can vary
doi: 10.1210/en.2014-1978 16 MacLuskyNJCookSScrocchiLShinJKimJVaccarinoFet al
Diabetes Care 43 , 14081415 (2020)
